Neuropsychological Outcome of Children Treated for Standard Risk Medulloblastoma in the PNET4 European Randomized Controlled Trial of Hyperfractionated Versus Standard Radiation Therapy and Maintenance Chemotherapy

被引:28
|
作者
Camara-Costa, Hugo [1 ]
Resch, Anika [2 ]
Kieffer, Virginie [3 ]
Lalande, Clemence [4 ]
Poggi, Geraldina [5 ]
Kennedy, Colin [6 ]
Bull, Kim [6 ]
Calaminus, Gabriele [7 ]
Grill, Jacques [4 ]
Doz, Francois [8 ,9 ]
Rutkowski, Stefan [2 ]
Massimino, Maura [10 ]
Kortmann, Rolf-Dieter [11 ]
Lannering, Birgitta [12 ]
Dellatolas, Georges [1 ]
Chevignard, Mathilde [13 ,14 ]
机构
[1] INSERM, Natl Inst Hlth & Med Res, U1178, Paris, France
[2] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[3] St Maurice Hosp, St Maurice, France
[4] Inst Gustave Roussy, Villejuif, France
[5] IRCCS Eugenio Medea, Sci Inst, Bosisio Parini, Lecco, Italy
[6] Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England
[7] Univ Munster, Paediat Oncol, D-48149 Munster, Germany
[8] Inst Curie, Paris, France
[9] Univ Paris 05, Sorbonne Paris Cite, Paris, France
[10] Fdn IRCCS, Ist Nazl Tumori, Milan, Italy
[11] Univ Leipzig, Dept Radiat Therapy, D-04109 Leipzig, Germany
[12] Univ Gothenburg, Paediat Oncol, Gothenburg, Sweden
[13] St Maurice Hosp, Rehabil Dept Children Acquired Neurol Injury, St Maurice, France
[14] UPMC Univ Paris, Univ Paris 04, INSERM, CNRS, Paris, France
关键词
QUALITY-OF-LIFE; PRIMITIVE NEUROECTODERMAL TUMORS; BRAIN-TUMORS; WHITE-MATTER; NEUROCOGNITIVE DEFICITS; CRANIAL RADIATION; CHILDHOOD; RADIOTHERAPY; SURVIVORS; IRRADIATION;
D O I
10.1016/j.ijrobp.2015.04.023
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: In the European HIT-SIOP PNET4 randomized controlled trial, children with standard risk medulloblastoma were allocated to hyperfractionated radiation therapy (HFRT arm, including a partially focused boost) or standard radiation therapy (STRT arm), followed, in both arms, by maintenance chemotherapy. Event-free survival was similar in both arms. Previous work showed that the HFRT arm was associated with worse growth and better questionnaire-based executive function, especially in children < 8 years of age at diagnosis. Therefore, the aim of this study was to compare performance-based cognitive outcomes between treatment arms. Methods and Materials: Neuropsychological data were collected prospectively in 137 patients. Using the Wechsler Intelligence Scales, Kaufman Assessment Battery for Children, and Raven's Progressive Matrices, we estimated full-scale intelligence quotient (FSIQ) and, when available, verbal IQ (VIQ), performance IQ (PIQ), working memory index (WMI), and processing speed index (PSI). Results: Among the 137 participants (HFRT arm n=71, STRT arm n=66, 63.5% males), mean (+/- SD) ages at diagnosis and assessment respectively were 9.3 (+/- 3.2) years of age (40.8% < 8 years of age at diagnosis) and 14.6 (+/- 4.3) years of age. Mean (+/- SD) FSIQ was 88 (+/- 19), and mean intergroup difference was 3.88 (95% confidence interval: -2.66 to 10.42, P = .24). No significant differences were found in children > 8 years of age at diagnosis. In children < 8 years of age at diagnosis, a marginally significant trend toward higher VIQ was found in those treated in the HFRT arm; a similar trend was found for PSI but not for PIQ, WMI, or FSIQ (mean intergroup differences were: 12.02 for VIQ [95% CI: 2.37-21.67; P=.02]; 3.77 for PIQ [95% CI: -5.19 to 12.74; P>.10]; 5.20 for WMI [95% CI: -2.07 to 12.47; P>.10]; 10.90 for PSI [95% CI: -1.54 to 23.36; P=.08]; and 5.28 for FSIQ [95% CI: -4.23 to 14.79; P>.10]). Conclusions: HFRT was associated with marginally higher VIQ in children < 8 years of age at diagnosis, consistent with a previous report using questionnaire- based data. However, overall cognitive ability was not significantly different. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:978 / 985
页数:8
相关论文
共 50 条
  • [41] Adaptlate -a randomized, controlled, open-label, phase-iii trial on adjuvant dynamic marker - adjusted personalized therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high risk, hr+/her2-early breast cancer
    Gluz, Oleg
    Degenhardt, Tom
    Marschner, Norbert
    Christgen, Matthias
    Kreipe, Hans Heinrich
    Nitz, Ulrike
    Kates, Ronald
    Schinkoethe, Timo
    Graeser, Monika
    Wurstlein, Rachel
    Kuemmel, Sherko
    Harbeck, Nadia
    CANCER RESEARCH, 2021, 81 (04)
  • [42] P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)
    Zebic, Danka Sinikovic
    Ben Tran
    Martin, Andrew James
    Pashankar, Farzana D.
    Mazhar, Danish
    Huddart, Robert A.
    Wheater, Matthew
    Walpole, Euan Thomas
    Dunwoodie, Elaine
    Feldman, Darren R.
    Birtle, Alison Jane
    Wyld, David
    Lawrence, Nicola Jane
    Stockler, Martin R.
    Grimison, Peter S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [43] P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediateand poor-risk metastatic germ cell tumours (GCTs).
    Zebic, Danka
    Stockler, Martin R.
    Martin, Andrew James
    Pashankar, Farzana D.
    Ben Tran
    Mazhar, Danish
    Huddart, Robert A.
    Wheater, Matthew
    Walpole, Euan Thomas
    Dunwoodie, Elaine
    Feldman, Darren R.
    Birtle, Alison Jane
    Stevanovic, Amanda Gwendolyn
    Wyld, David
    Hanning, Fritha J.
    Grimison, Peter S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [44] P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumors (GCTs).
    Subramaniam, Shalini
    Toner, Guy C.
    Stockler, Martin R.
    Martin, Andrew James
    Pashankar, Farzana D.
    Tran, Ben
    Jeffery, Mark
    Mazhar, Danish
    Huddart, Robert A.
    Walpole, Euan Thomas
    Stevanovic, Amanda Gwendolyn
    Wyld, David
    Hanning, Fritha J.
    Wheater, Matthew James
    Balagtas, Jay R.
    Troon, Simon
    Birtle, Alison Jane
    White, Jeff D.
    Grimison, Peter S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [45] ADAPTlate: A randomized, controlled, open-label, phase III trial on adjuvant dynamic marker-Adjusted personalized therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high-risk, HR+/HER2-early breast cancer.
    Gluz, Oleg
    Scheffen, Iris
    Degenhardt, Tom
    Marschner, Norbert Walter
    Christgen, Matthias
    Kreipe, Hans Heinrich
    Nitz, Ulrike
    Kates, Ronald E.
    Schinkoethe, Timo
    Graeser, Monika Karla
    Wuerstlein, Rachel
    Kuemmel, Sherko
    Bauer, Lelia
    Schem, Christian
    Fehm, Tanja N.
    Neubauer, Hans
    Harbeck, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [46] Point-of-care HIV viral load and targeted drug resistance mutation testing versus standard care for Kenyan children on antiretroviral therapy (Opt4Kids): an open-label, randomised controlled trial
    Patel, Rena C.
    Oyaro, Patrick
    Thomas, Katherine K.
    Wagude, James
    Mukui, Irene
    Brown, Evelyn
    Hassan, Shukri A.
    Kinywa, Eunice
    Oluoch, Frederick
    Odhiambo, Francesca
    Oyaro, Boaz
    Kingwara, Leonard
    Karauki, Enericah
    Yongo, Nashon
    Otieno, Lindah
    John-Stewart, Grace C.
    Abuogi, Lisa L.
    LANCET CHILD & ADOLESCENT HEALTH, 2022, 6 (10): : 681 - 691
  • [47] First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study
    Brack, Eva
    Bodmer, Nicole
    Simon, Arne
    Leibundgut, Kurt
    Kuehne, Thomas
    Niggli, Felix K.
    Ammann, Roland A.
    PEDIATRIC BLOOD & CANCER, 2012, 59 (03) : 423 - 430
  • [48] First-Day Step-Down to Oral Outpatient Treatment versus Continued Standard Treatment in Children with Cancer and Low-Risk Fever in Neutropenia. A Randomized Controlled Trial within the Multicenter SPOG 2003 FN Study
    Brack, Eva
    Bodmer, Nicole
    Simon, Arne
    Leibundgut, Kurt
    Kuhne, Thomas
    Niggli, Felix K.
    Ammann, Roland A.
    SWISS MEDICAL WEEKLY, 2012, 142 : 5S - 6S
  • [49] PANTHER: Prospective randomized phase III trial of tailored and dose-dense versus standard tri-weekly adjuvant chemotherapy for high-risk breast cancer in the modern era of endocrine and anti-HER2 therapy.
    Bergh, Jonas C. S.
    Foukakis, Theodoros
    von Minckwitz, Gunter
    Bengtsson, Nils-Olof
    Wallberg, Birgitta
    Fornander, Tommy
    Mlineritsch, Brigitte
    Schmatloch, Sabine
    Singer, Christian F.
    Steger, Guenther G.
    Karlsson, Eva
    Carlsson, Lena
    Loibl, Sibylle
    Untch, Michael
    Hellstrom, Mats
    Johansson, Hemming
    Malmstrom, Per
    Gnant, Michael
    Greil, Richard
    Moebus, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [50] DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)-A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation
    Niazi, Tamim
    McBride, Sean Matthew
    Williams, Scott
    Davis, Ian D.
    Stockler, Martin R.
    Martin, Andrew James
    Bracken, Karen
    Roncolato, Felicia
    Horvath, Lisa
    Sengupta, Shomik
    Martin, Jarad
    Lim, Tee
    Hughes, Simon
    McDermott, Raymond S.
    Catto, James W. F.
    Kelly, Paul J.
    Parulekar, Wendy R.
    Morgan, Scott Carlyle
    Rendon, Ricardo A.
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)